Literature DB >> 18513991

Growth-arrest-dependent expression and phosphorylation of p27kip at serine10 is mediated by the JNK pathway in C6 glioma cells.

Kirsten Mielke1.   

Abstract

Induction of growth arrest by differentiation is an attractive therapeutic strategy against glioma cell proliferation and tumorigenicity. The observation that the expression of the JNK3 gene is lost in many human gliomas makes the JNK pathway an interesting target for investigation. Here, the influence of the JNK pathway on the differentiation of C6 glioma cells was investigated using pharmacological inhibition and JNK3 knockdown. Growth arrest induced the expression of JNK3 on transcriptional and translational level, whereas the expression of the cell cycle inhibitor p27kip was induced on the translational level only. Transient depletion of JNK3 in growth arrested C6 cells resulted in an about 40% decrease in cell adhesion and almost completely abolished the induction in p27kip protein. In addition, overexpression of wild type JNK3 in proliferating C6 cells led to a marked inhibition of proliferation. Beside synthesis, the amount of p27kip protein is regulated by its stability, which is known to be enhanced by phosphorylation at serine10 of p27kip. Here, the JNKs were identified as kinases that are able to phosphorylate p27kip at Ser10. As a result, the stability of p27kip protein is reduced by inhibition of the JNK pathway. These results suggest that the JNK pathway influences the stability of p27kip by phosphorylation of serine10 and that JNK3 is responsible for the translational activation of p27kip protein expression in growth arrested C6 glioma cells and therefore cell cycle arrest.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18513991     DOI: 10.1016/j.mcn.2007.12.007

Source DB:  PubMed          Journal:  Mol Cell Neurosci        ISSN: 1044-7431            Impact factor:   4.314


  2 in total

1.  Reprogramming-derived gene cocktail increases cardiomyocyte proliferation for heart regeneration.

Authors:  Yuan-Yuan Cheng; Yu-Ting Yan; David J Lundy; Annie Ha Lo; Yu-Ping Wang; Shu-Chian Ruan; Po-Ju Lin; Patrick Ch Hsieh
Journal:  EMBO Mol Med       Date:  2017-02       Impact factor: 12.137

2.  Monoclonal antibodies to activated CDK4: use to investigate normal and cancerous cell cycle regulation and involvement of phosphorylations of p21 and p27.

Authors:  Katia Coulonval; Vincent Vercruysse; Sabine Paternot; Jaime M Pita; Robert Corman; Eric Raspé; Pierre P Roger
Journal:  Cell Cycle       Date:  2021-12-16       Impact factor: 4.534

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.